Medical technology startup BellaSeno has released encouraging one-year follow-up data for its 3D-printed absorbable breast implants. The custom-made implants were well tolerated by patients. Now BellaSeno plans to expand the clinical trial.
In the study, both the Pectus and breast implants showed a very good safety profile. They were positively accepted by surgeons and patients expressed high satisfaction with a significant improvement in their quality of life. In particular, breast reconstruction patients who had previously had silicone implants experienced a significant reduction in pain. After surgery, all patients’ breasts maintained their shape and volume.
The majority of study participants have already been treated, and all patients are expected to undergo surgery by the end of the year. Based on these results, BellaSeno plans to expand the study to multiple centers in Europe and Australia.
With its resorbable breast and pectus excavatum support structures, BellaSeno has developed groundbreaking 3D-printed products for plastic and reconstructive surgery. The company has already demonstrated superior properties of its medical support structures and presented the data at scientific meetings and in peer-reviewed publications.
“The positive one-year follow-up is a key milestone for our breast and pectus excavatum scaffolds,” said Mohit Chhaya, CEO of BellaSeno. “The data brings us closer to realizing our vision of providing breakthrough innovations in the world of breast surgery by offering personalized care options. First-in-human data have been very promising so far, demonstrating excellent safety of the scaffolds and high accpetance of the products among surgeons and patients. Moreover, patient recruitment is going well, which confirms that there is a significant need for alternatives to silicone implants.”
Subscribe to our Newsletter
3DPresso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.
